We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · September 28, 2020

ESMO 2020: Trabectedin No Better Than Carboplatin When Combined With Pegylated Liposomal Doxorubicin for Recurrent Ovarian Cancer

Results of INOVATYON suggest platinum-based regimens remain the standard of care

PracticeUpdate Editorial Team


Further Reading